MIRA Pharmaceuticals (MIRA) Insider Paul Buys 50,000 Shares

On June 12, 2026, insider Matthew Paul Del Giudice purchased 50,000 shares of MIRA. This move suggests a vote of confidence in the company, as the stock trades around $0.93.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

Several insiders, including Matthew Paul Del Giudice, bought 50,000 shares each of MIRA on June 12, 2026. Other insiders such as Edward Clouston Macpherson, Matthew Pratt Whalen, and Denil Nanji Shekhat also made similar purchases on the same day. Erez Aminov, CEO and Chairman, had previously acquired over 3.15 million shares on December 17, 2025.

Other Institutional Activity in MIRA

In recent activity, Vanguard Capital Management LLC significantly increased its position by adding 693,912 shares, bringing its total to 693,912 shares valued at about $742,486. Geode Capital Management, LLC also expanded its holdings by 18,012 shares, ending with 290,890 shares worth approximately $311,251. Meanwhile, BlackRock, Inc. added 2,577 shares, for a total of 112,346 shares valued at $120,210. However, Suncoast Equity Management reduced its stake by 12,644 shares, now holding 90,645 shares valued at $96,990.

MIRA Pharmaceuticals, Inc. Stock Up 12.0%

Shares of MIRA are trading near $0.93. The stock has seen various institutional activities, reflecting diverse investor strategies. Despite the lack of current earnings or dividend data, the insider and institutional movements indicate ongoing interest in the stock.

Bottom Line

The recent insider buying activity at MIRA, especially by Matthew Paul Del Giudice and other key figures, indicates confidence in the company's prospects. With the stock trading at about $0.93, investors are closely watching these transactions. Institutional investors have also made notable moves, adding to the dynamic picture of MIRA's ownership landscape.